GlassScriptPhysician profile
Terry P Bell
NPI 1639186596
$14,134.68
in general payments reported to CMS, 2019-2025
39 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,262 · 2020: $2,344 · 2021: $2,395 · 2022: $2,043 · 2023: $1,722 · 2024: $1,905 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,091.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,261.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,913.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,553.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,323.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $985.37 | 2021-2025 | |
| Pfizer INC. | $687.77 | 2019-2025 | |
| Amgen INC. | $655.11 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $580.91 | 2019-2022 | |
| Abbvie INC. | $502.39 | 2021-2025 | Vraylar, Qulipta |
| Janssen Pharmaceuticals, INC | $462.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $358.06 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $302.31 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $277.18 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $251.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.35 | 2019-2024 | Xifaxan, Trulance |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.